Haldol

Haldol is the brand name for the oral antipsychotic medication haloperidol, a typical butyrophenone commonly used in the European market. It acts as a dopamine D2 receptor antagonist and is prescribed by healthcare professionals for several psychiatric conditions. The formulation is supplied in tablet form, although specific strengths may vary by manufacturer. Haldol is generally a prescription‑only product and is not classified as a controlled substance.

Haloperidol (brand name Haldol) is prescribed for a range of psychiatric conditions and behavioral symptoms.

- Schizophrenia, including maintenance therapy and relapse prevention. - Acute psychotic episodes, such as those associated with bipolar disorder or substance‑induced states. - Tourette syndrome, to reduce motor and vocal tics. - Severe agitation or aggression, particularly when rapid control is required. - Off‑label use for certain behavioral disturbances in dementia, when other options are unsuitable. - Adjunctive treatment for psychosis in Parkinson’s disease when benefits outweigh motor side effects.

Haloperidol may produce a range of adverse effects that vary in frequency and severity.

Common: - Drowsiness or sedation, which may affect alertness and coordination. - Extrapyramidal symptoms such as tremor, muscle rigidity, or akathisia (restlessness). - Dry mouth, constipation, and reduced gastrointestinal motility. - Blurred vision, dizziness, or orthostatic light‑headedness. - Weight gain or changes in appetite.

Serious: - Neuroleptic malignant syndrome, a rare but potentially fatal reaction characterized by high fever, muscle rigidity, and autonomic instability. - Cardiac arrhythmias, including torsades de pointes or prolonged QT interval, which can lead to syncope or sudden death. - Severe hypotension or syncope, especially when standing quickly after a dose. - Elevated liver enzymes indicating possible hepatic injury.

When prescribing haloperidol, clinicians consider several precautionary factors to minimize risk and ensure safe use.

- Assess for a history of cardiovascular disease, as haloperidol can affect heart rhythm. - Monitor for signs of extrapyramidal symptoms, especially in patients with Parkinsonian features. - Use caution in patients with hepatic or renal impairment; dose adjustments may be required. - Evaluate pregnancy and breastfeeding status, because safety data are limited. - Review concomitant medications that prolong the QT interval. - Consider age‑related sensitivity, particularly in elderly patients at risk of falls.

Haloperidol can interact with other medicines, altering its effectiveness or increasing the chance of adverse reactions.

Avoid: - Concurrent use with other strong dopamine antagonists, which may intensify extrapyramidal effects. - Combining with medications that markedly prolong the QT interval, such as certain antiarrhythmics or fluoroquinolones. - Use with MAO inhibitors, which can increase the risk of severe hypotension.

Use with caution: - Co‑administration with anticholinergic agents; they may mask early signs of extrapyramidal symptoms. - Concurrent CNS depressants (e.g., benzodiazepines, opioids) may enhance sedation. - Adjust dose when given with CYP3A4 inhibitors or inducers, as they affect haloperidol metabolism.